2 нояб. 2021 г. · For type1 and type2 pRCC, 3-years PFS was 93.0% and 74.9%, respectively. Survival of type1 pRCC was better than that of type2 (P= 0.027).

17 янв. 2023 г. · Median progression-free survival (PFS) for pRCC patients was 1.8 months with IFN versus 3.8 months with temsirolimus (95% CI, 0.28–0.83). Median ...

Here the 5-year survival rates were 73.2%, 79.4% and 87.9% for localised cRCC, pRCC and chromophobe RCC. However, multivariate analyses only identified the TNM ...

The overall and disease-free survival rate was 89% and 92% in type 1 tumors and 55% and 44% in type 2 tumors, respectively. Univariate analysis identified tumor ...

The cumulative incidence of disease recurrence was 5.9% at 1 year, 9% at 2 years, and 11.7% at 5 years. The first site of recurrent disease was the chest in 30 ...

For those with PRCC diagnosed in stage 1, the odds of surviving five years or longer are better than 80 percent. In more advanced stages, survival rates decline ...

3 дек. 2020 г. · During a median follow-up period of 61.4 months, 1-year cancer specific survival (CSS) of the type I was 100%, 5-year CSS was 95.2%, the 1-year ...

17 мар. 2020 г. · They also can't consider newer treatments being developed. In general, type 2 papillary renal cell carcinoma has a poorer prognosis than type 1.

17 апр. 2023 г. · Early detection and better treatments have increased the survival rate. The five-year survival rate for Stage I RCC is 90%. And while the life ...